• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.
【24h】

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.

机译：单克隆抗体和抗体片段：非血液肿瘤治疗的最新进展和未来展望。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. AREAS COVERED: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. EXPERT OPINION: Monoclonal antibodies were initially developed in order to avoid the cytotoxic effects of chemotherapy on healthy tissues. However antibodies have not yet replaced chemotherapy agents, since the combination of both kinds of drugs have usually appeared to achieve higher benefit compared with chemotherapy alone. The research for the development of new monoclonal antibodies aims to identify further targets and to provide innovative antibody constructs.
机译：简介：单克隆抗体的使用是靶向癌症生长和存活主要途径特定关键点的策略之一，但是只有少数抗体在治疗非血液系统恶性肿瘤方面具有明显的临床益处。涵盖领域：本综述总结了单克隆抗体的一般特性，包括结构，命名和生产技术。简要介绍了已批准在临床实践中用于治疗非血液系统肿瘤的抗体，以及在这种情况下仍在开发的那些抗体。还报道了抗体片段的类型。专家意见：最初开发单克隆抗体是为了避免化学疗法对健康组织的细胞毒性作用。但是，抗体尚未取代化疗药物，因为与单独化疗相比，两种药物的组合通常表现出更高的获益。新单克隆抗体开发的研究旨在确定其他靶标并提供创新的抗体构建体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号